Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and offers medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers, as well as provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. Cardinal Health, Inc. was founded in 1979 and is headquartered in Dublin, Ohio.
IPO Year:
Exchange: NYSE
Website: cardinalhealth.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/3/2025 | $179.00 | Equal Weight → Overweight | Wells Fargo |
| 2/5/2025 | $140.00 → $150.00 | Hold → Buy | Jefferies |
| 1/8/2025 | $130.00 → $144.00 | Hold → Buy | TD Cowen |
| 1/7/2025 | $140.00 | In-line → Outperform | Evercore ISI |
| 1/6/2025 | $132.00 → $145.00 | Neutral → Buy | BofA Securities |
| 12/13/2024 | $101.00 → $127.00 | Underweight → Equal Weight | Wells Fargo |
| 12/4/2024 | $139.00 | Outperform | Mizuho |
| 2/26/2024 | $125.00 | Outperform | Leerink Partners |
| 2/9/2024 | Hold → Buy | Argus | |
| 1/3/2024 | $117.00 | Overweight | Barclays |
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /PRNewswire/ -- After the close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), doctors, scientists, and researchers are optimistic, especially in the fields of immunotherapy, Car T-cell therapy, liquid biopsies, breast cancer, AI, and even exercise. However, with reports coming out that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. For inv
NEW YORK, June 12, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Kristen Scholer delivers the pre-market update on June 12th Stocks are down fractionally this morning after the S&P 500 ended a three-day win streak yesterday. The major index is about 2% from its record.Amid the market momentum, Voyager Technologies (NYSE:VOYG) and Ategrity (NYSE: ASIC) popped double digits in their debuts yesterday. Voyager is a $3.1 billion space and defense company. Ategrity is an insurer valued at about $1.2 billio
Key announcements: Raising FY25 non-GAAP diluted EPS guidance to $8.15 to $8.201Establishing preliminary FY26 non-GAAP diluted EPS guidance of $9.10 to $9.30 (13% growth at the mid-points)2Confirming long-term target of 12% to 14% non-GAAP diluted EPS CAGR for FY26 to FY283Raising long-term target for Pharmaceutical and Specialty Solutions profit to 5% to 7% normalized growth3,4Raising long-term target for Other profit to ~10% normalized growth3,4,5Updating GMPD long-term target to $50M+ of profit growth per year after FY26Expecting at least $10B in total adjusted free cash flow over next three yearsRaising baseline share repurchase plans to at least $750M per yearCompany reiterating strateg
Agreement supports the upcoming launch of LYMPHIR for the treatment of cutaneous T-cell lymphoma CRANFORD, N.J., June 9, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that it has entered into a distribution services agreement with Cardinal Health (NYSE:CAH), a leading provider of pharmaceutical and specialty pharmaceutical distribution services in the United States. This agreement is designed to help provide access to LYMPHIR™ (denileukin dif
Kendall DL™ Multi System simplifies patient monitoring, drives efficiencies for providers DUBLIN, Ohio, June 4, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today the U.S. launch of its multi-parameter, single-patient use monitoring cable and lead wire system that enables the continuous monitoring of cardiac activity, blood oxygen level and temperature with one point of connection. The new Kendall DL™ Multi System is designed to travel with the patient from admission to discharge for smooth transport. It helps improve clinician workflows, provides reliable monitoring to help determine the best course of care, and maximizes value across the hospital.
Carlisle Companies Incorporated (NYSE:CSL) today announced the appointment of Christopher B. Gaskill as Vice President & General Counsel for the Company. In conjunction with this appointment, Scott C. Selbach will transition to a new role as Executive Vice President, Government Relations for the Company. Mr. Selbach will also remain Secretary of the Company. Both Mr. Gaskill and Mr. Selbach will report to Chris Koch, Carlisle's Chair, President & Chief Executive Officer. Prior to joining Carlisle, Mr. Gaskill served as Executive Vice President, Chief Legal Officer, and Secretary at Summit Materials, Inc. (NYSE:SUM), where he was responsible for the company's global legal functions and ensu
Analysis charts the emergence and future of advanced therapies DUBLIN, Ohio, May 7, 2025 /PRNewswire/ -- Today, Cardinal Health (NYSE:CAH) released its 2025 Advanced Therapies Report: Revolutionizing patient care – the promise and potential of cell and gene therapies, providing insights into the evolving landscape of cell and gene therapies (CGTs). This inaugural report is based on a comprehensive survey of more than 100 healthcare providers as well as interviews with subject matter experts and a patient who received CAR T-cell therapy, all of whom provide valuable insights in
DUBLIN, Ohio, May 5, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved an increase to its quarterly dividend, to $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on July 15, 2025, to shareholders of record at the close of business on July 1, 2025. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an op
Revenue was flat at $54.9 billion; revenue increased 19% excluding the impact of the previously communicated customer contract expirationGAAP1 operating earnings were $730 million; GAAP diluted EPS was $2.10Non-GAAP operating earnings increased 21% to $807 million, driven by segment profit growth across all of the company's operating segments; non-GAAP diluted EPS increased 13% to $2.35Fiscal year 2025 non-GAAP EPS guidance2 raised and narrowed to $8.05 to $8.15, from $7.85 to $8.00GI Alliance announces expansion into urology specialty therapeutic areaDUBLIN, Ohio, May 1, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported third quarter fiscal year 2025 revenues of $54.9 billion,
MELBOURNE, Australia and INDIANAPOLIS, April 08, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, Telix, the Company) today announces that it has selected Cardinal Health, Inc. (NYSE:CAH, Cardinal Health)) as one of its commercial radiopharmaceutical distributors to supply finished unit doses of Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), Telix's next-generation PSMA-PET imaging1 agent for prostate cancer in the United States (U.S.). Following recent U.S. Food and Drug Administration (FDA) approval2, and in preparation for commercial launch in H1 2025, Telix has contracted with Cardinal Health to enable availability acr